Ovarian function is an active frontier of cell therapy research.
Hormonal aging is marketed harder than almost anything else in this field, so precision matters here more than anywhere. The genuine human research is concentrated in premature ovarian insufficiency, where ovarian function declines decades early, and some of it is striking.
This page separates what has actually been studied from what is being sold, and explains what a responsible review looks like for hormonal health.
Aurenza does not claim that regenerative medicine treats or reverses menopause, ovarian insufficiency, or any hormonal condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Hormonal health is marketed harder than almost anything else in this field, so precision matters here more than anywhere. The genuine human research is concentrated in premature ovarian insufficiency, where ovarian function fails decades early, and some of it is striking.
A 2020 clinical study in Cell Proliferation treated 61 women diagnosed with premature ovarian insufficiency using umbilical cord MSCs cultured to GMP standard, delivered by ultrasound-guided injection into the ovary. The full open-access report describes no serious side effects or treatment-related complications, increased follicular development and improved egg collection, and four successful live births among participants, with the best responses in women with shorter duration of amenorrhea and better baseline ovarian condition.
Across the early clinical literature, including first-in-human intra-ovarian transplantation studies, a 2025 review in Stem Cell Reviews and Reports describes reported outcomes in some patients including improved hormonal profiles, increased antral follicle counts, resumption of menstruation, and occasional spontaneous pregnancies.
The Honest Line
Read carefully what that research is about: premature ovarian insufficiency, a defined medical condition managed under formal clinical guidelines from ESHRE and reviewed in the New England Journal of Medicine. It is not about typical menopause, which has essentially no controlled human cell therapy evidence behind it, and the same 2025 review states the limitations plainly: small samples, mostly no control groups, variable cell sources and doses, and short follow-up. No study shows a guarantee it works every time, or that it will work for you, and hormone therapy for menopausal symptoms remains established, guideline-supported medicine that belongs in any honest conversation with your own physician.
Why This Is Exactly Where a Candidacy Review Comes In
Hormonal status is precisely measurable, which makes this the category where a labs-first review earns its keep most obviously: your actual diagnosis, not your symptoms alone, decides whether the research above has anything to do with you. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
What to Ask Any Provider
Which studies are you citing, and were they conducted in women with my actual diagnosis? Have you discussed established hormone therapy options with me honestly? What is being administered, where, and at what verified cell count? What would make me a poor candidate? How will change be measured on labs rather than impressions?
The Honest Limits
Individual results cannot be predicted or guaranteed. These applications are not FDA approved, and any procedure takes place in Mexico under COFEPRIS regulation. Established options for menopausal symptoms exist and should be part of any honest conversation with your own physician.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.